热门资讯> 正文
由于基因治疗担忧，RBC Capital的Sarepta评级被下调
2025-03-31 22:54
- Sarepta Therapeutics (SRPT) has been downgraded to Sector Perform from Outperform at RBC Capital, citing increased uncertainty surrounding its gene therapy Elevidys.
- "We are incrementally less bullish on Elevidys’s opportunity following recent physician checks indicating only a moderate sense of urgency to treat DMD patients—not helped by the recently announced death—and we have less confidence they can beat medium-term numbers meaningfully enough to diminish the lingering overhangs around revenue durability for the one-time treatment," analysts at RBC Capital said.
- Additionally, regulatory uncertainty has grown after the resignation of Dr. Peter Marks, a key FDA advocate for gene therapies, RBC Capital added.
- The research broker also cut its PT for the company to $87 from $161.
- Stock is down about 7.3% in morning trade.
More on Sarepta Therapeutics
- Sarepta: Should Investors Run For The Exit?
- Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
- Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
- Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio
- Biggest stock movers Tuesday: GRAB, BIDU, SRPT, and more
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
